Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43845   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-002487-41
    Sponsor's Protocol Code Number:GLY-321-2017
    National Competent Authority:Denmark - DHMA
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2017-12-11
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedDenmark - DHMA
    A.2EudraCT number2017-002487-41
    A.3Full title of the trial
    A Phase Ib/IIa open-label, repeated dose, metabolic balance study of FE 203799 in patients with short bowel syndrome
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    An open-label phase Ib / IIa metabolic balance test of FE 203799 in patients with short-term syndrome
    Et åben-label fase Ib/IIa metabolisk balanceforsøg af FE 203799 i patienter med korttarmssyndrom
    A.4.1Sponsor's protocol code numberGLY-321-2017
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGLyPharma Therapeutic Inc. (a wholly owned subsidiary of VectivBio Holding AG)
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGlypharma (a wholly owned subsidiary of VectivBio Holding AG
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGLyPharma Therapeutic Inc. (a wholly owned subsidiary of VectivBio Holding AG)
    B.5.2Functional name of contact pointChristian Meyer
    B.5.3 Address:
    B.5.3.1Street AddressAeschenvorstadt 36
    B.5.3.2Town/ cityBasel
    B.5.3.3Post code4051
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number0041796543455
    B.5.6E-mailchristian.meyer@vectivbio.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code FE 203799
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNNone
    D.3.9.1CAS number 1295353-98-8
    D.3.9.2Current sponsor codeFE 203799
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Short bowel syndrome (SBS)
    E.1.1.1Medical condition in easily understood language
    Patients with SBS with intestinal failure have a reduced absorption in the intestines. Shortened intestines also lead to a changed hormone production.
    E.1.1.2Therapeutic area Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10049416
    E.1.2Term Short-bowel syndrome
    E.1.2System Organ Class 10017947 - Gastrointestinal disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the safety and tolerability of FE 203799 in patients with SBS
    E.2.2Secondary objectives of the trial
    •To assess the PD of FE 203799 in patients with SBS
    •To assess the PK of FE 203799 in patients with SBS with
    •To compare the PD and PK between SBS patients with intestinal insufficiency (SBS-II) and SBS patients with intestinal failure (SBS-IF)
    •To evaluate markers indicative of a pharmacological effect of FE 203799
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1.Males and females with SBS-II secondary to surgical resection of the small intestine, with or without an intact colon
    2.18-80 years of age
    3.Average faecal wet weight excretion of ≥1500 g/day during the baseline balance study
    4.Average urine production <2000 mL/day during the baseline balance study
    5.Body Mass Index (BMI) between 16.0 and 32.0 (both inclusive)
    6.At least 6 months since last surgical bowel resection
    7.Willing to adhere to a defined oral intake of fluids on certain days as required by the protocol (and based on the individual’s routine daily consumption)
    8.Women of childbearing potential must agree to use an adequate method of contraception during the trial and for 60 days after the end-of-trial visit. Adequate methods of contraception include intrauterine device or hormonal contraception (oral contraceptive pill, depot injections or implant, transdermal depot patch or vaginal ring). To be considered sterilised or infertile, females must have undergone surgical sterilisation (bilateral tubectomy, hysterectomy or bilateral ovariectomy) or be post-menopausal (defined as at least 12 months amenorrhoea may be confirmed with follicle-stimulating hormone [FSH] test if there is doubt)
    9. Male subjects must commit to use barrier contraception (e.g. condom) during the trial and for 2-weeks after the end-of-trial visit
    E.4Principal exclusion criteria
    1.Pregnancy or lactation
    2.Positive results on the human immunodeficiency virus (HIV), hepatitis B and/or C tests
    3.A history of clinically significant intestinal adhesions and/or chronic abdominal pain
    4.Require chronic systemic narcotics for treatment of pain that exceeds an amount corresponding to 80 mg of morphine per day
    5.History of cancer or clinically significant lymphoproliferative disease within ≤5 years, except for adequately treated basal cell skin cancer
    6.History of gallstone within the past 3 years. Gallstone with subsequent cholecystectomy to resolve the issues is acceptable.
    7.Inflammatory bowel disease patients (IBD) who have NOT been on a stable drug treatment regimen for at least the past 4 weeks
    8.Evidence of active IBD in the past 12 weeks
    9.Visible blood in the stool within the last 3 months
    10.Decompensated heart failure (New York Heart Association [NYHA] class III-IV, see Appendix 12.2) and/or known coronary heart disease defined as unstable angina pectoris and/or myocardial infarction within the last 6 months prior to screening
    11.Radiation enteritis, scleroderma or other condition of intestinal dysmotility, coeliac disease, refractory or tropical sprue
    12.History of alcohol and/or drug abuse within the last 12 months
    13.Inadequate hepatic function as defined by: bilirubin >upper limit of normal (ULN), alanine transaminase (ALT) or aspartate transaminase (AST) >2.0 × ULN; alkaline phosphatase (ALP) >2.5 × ULN; or international normalised ratio (INR) >1.5 × ULN
    14.Inadequate renal function as defined by serum creatinine or blood urea nitrogen >2.5 x ULN
    15.Unplanned hospitalisation of >24 hours duration within 1 month before the screening visit
    16.Changes in systemic corticosteroids, methotrexate, cyclosporine, tacrolimus, sirolimus, infliximab, or other biologic therapy/immune modifiers within 3 months of screening
    17.Any use of growth hormone, glutamine or growth factors such as native GLP-2 or GLP-2 analogue within the last 3 months
    18.Any use of antibiotics within the last 30 days
    19.Participation in another clinical trial (except studies with catheter locks) within the last 3 months and during this trial
    20.Previously been treated in this trial
    21.Loss of blood or donation of blood or plasma >500 mL within 3 months prior to screening
    22.Patient not capable of understanding or not willing to adhere to the trial visit schedules and other protocol requirements
    23.For any other reason judged not eligible by the investigator
    24. Catheter sepsis experienced within the last 3 months
    E.5 End points
    E.5.1Primary end point(s)
    •Adverse events (AEs; type, frequency and intensity), vital signs (systolic and diastolic blood pressure, heart rate), electrocardiogram (ECG; intervals, rhythm and morphology), clinical chemistry, haematology, haemostasis and urinalysis
    E.5.1.1Timepoint(s) of evaluation of this end point
    From screening visit to end of study, in total during approximately 14 weeks per patients.
    An AE having onset after the first administration of trial drug is considered treatment emergent.
    E.5.2Secondary end point(s)
    •Changes in faecal excretion of wet weight, energy, macronutrients (carbohydrate, nitrogen as a marker for protein and lipids) and electrolytes (sodium, potassium, calcium and magnesium) over 72 hours from baseline to end of treatment
    •Changes in urine output and urinary electrolytes (sodium, potassium, calcium and magnesium) over 72 hours from baseline to end of treatment
    •Changes in dietary intake of wet weight, energy, macronutrients (carbohydrate, nitrogen as a marker for protein and lipids) and electrolytes (sodium, potassium, calcium and magnesium) over 72 hours from baseline to end of treatment
    •Changes in absolute and relative absorption of wet weight, energy, macronutrients (carbohydrate, nitrogen as a marker for protein and lipids) and electrolytes (sodium, potassium, calcium and magnesium) over 72 hours from baseline to end of treatment
    •Change in body weight from baseline to end of treatment
    •Changes from baseline in lean body mass, bone mineral content and fat mass by dual-energy X-ray absorptiometry (DEXA) scan from baseline to end of treatment
    •Change in plasma citrulline level from baseline to end of treatment
    •FE 203799 PK parameters: Cmax, Tmax, AUCτ, AUCτ/dose, λZ, terminal T½, CL/F, V/F, Fluctuation index
    E.5.2.1Timepoint(s) of evaluation of this end point
    The secondary efficacy endpoints are all concerned with the change from baseline to the end of treatment for the following parameters:
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Metabolic balance, changes in urine output, citrulline blood analyse, and local tolerability.
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    repeated dose
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 6
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 2
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-01-31
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-01-23
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2019-10-28
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 19 07:37:35 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA